)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Xtant Medical
Xtant Medical (XTNT) investor relations material
Xtant Medical Canaccord Genuity's 46th Annual Growth Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Canaccord Genuity's 46th Annual Growth Conference summary11 Aug, 2026
Market opportunity and business strategy
Addressing a $3 billion domestic orthobiologics market and $1 billion hemostasis market, with additional adjacent opportunities targeted.
Recent acquisition of Dilon Technologies' HEMOBLAST distribution expands reach and product portfolio.
Expanded sales force from 4 to 25 reps, enabling broader access to over 650 independent agents and 450+ IDN/GPO contracts.
Divested non-core assets, freeing up cash and sharpening focus on regenerative biologics.
Strategic diversification into sports medicine, surgical repair, and advanced wound care to increase hospital relevance.
Product innovation and pipeline
Launched seven new products since 2024, including four in new categories such as growth factor, amnio, and stem cells.
Trivium enhanced DBM product line and CollagenX have driven recent growth; E-Matrix collagen product to launch soon.
Pipeline includes OsteoSelect fiber, CollagenX Pro, and further expansion of regenerative biologics.
HEMOBLAST acquisition supports a comprehensive biologics offering for hospitals.
Financial performance and outlook
Revenue reached over $134 million last year, with a current year midpoint guidance of $101 million after divestitures.
$21.4 million in cash generated from asset sales used to reduce debt and reinvest in core business.
$5 million paid for HEMOBLAST rights, expensed in the quarter, impacting short-term loss but expected to drive future cash generation.
Expecting to generate cash and not require additional capital by Q4 this year.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xtant Medical
- Expanded into hemostatic biologics, strengthened balance sheet, and drove innovation for growth.XTNT
Investor presentation - Revenue and margins declined, with a net loss and lower guidance amid supply chain risks.XTNTQ2 2026
- Strong growth, margin expansion, and strategic acquisitions position the business for continued outperformance.XTNTCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase
- Key votes include director elections, auditor ratification, and executive pay approval.XTNTProxy filing
- Board recommends approval of all proposals, including director elections and executive pay.XTNTProxy filing
- Raised 2026 revenue guidance to $101M–$105M amid asset sales, new launches, and debt reduction.XTNTQ1 2026
- Strong 2025 growth, margin expansion, and innovation fuel expansion in orthobiologics and beyond.XTNTInvestor presentation
- Q3 2024 revenue up 12% year-over-year; full-year guidance reaffirmed at $116M–$120M.XTNTQ3 2024
- 2024 revenue up 28% to $117.3M; 2025 guidance $126–$130M, margin and cash flow gains expected.XTNTQ4 2024
Next Xtant Medical earnings date
Q3 202616 Nov, 2026
Xtant Medical
Next Xtant Medical earnings date
Q3 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Xtant Medical Holdings Inc develops and manufactures regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The Company's OsteoSponge biomaterial is a natural scaffold used to promote bone formation or repair. Its other products include OsteoStop, an autologous cell therapy that induces a pro-inflammatory response to reduce endothelial cell activation, OsteoSelect DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor cream that contains various proteins and peptides that support bone formation and remodeling.